High-throughput next-generation sequencing (NGS) provides insights into genome-wide mutations and can be used to identify biomarkers for the prediction of immune and targeted responses. A deeper understanding of the molecular biological significance of genetic variation and effective interventions is required and ultimately needs to be associated with clinical benefits. We conducted a retrospective observational study of patients in two cancer cohorts who underwent NGS in a “real-world” setting. The association between differences in tumor mutational burden (TMB) and clinical presentation was evaluated. We aimed to identify several key mutation targets and describe their biological characteristics and potential clinical value. A pan-cancer ...
BackgroundTumor mutation burden (TMB) has been recognized as a predictive biomarker for immunotherap...
Molecular profiling with next generation sequencing (NGS) delivers key information on mutant gene se...
Tumor mutational burden (TMB) is a promising predictive biomarker for cancer immunotherapy. Patients...
High-throughput next-generation sequencing (NGS) provides insights into genome-wide mutations and ca...
High-throughput next-generation sequencing (NGS) provides insights into genome-wide mutations and ca...
High-throughput next-generation sequencing (NGS) provides insights into genome-wide mutations and ca...
High-throughput next-generation sequencing (NGS) provides insights into genome-wide mutations and ca...
High-throughput next-generation sequencing (NGS) provides insights into genome-wide mutations and ca...
High-throughput next-generation sequencing (NGS) provides insights into genome-wide mutations and ca...
High-throughput next-generation sequencing (NGS) provides insights into genome-wide mutations and ca...
High-throughput next-generation sequencing (NGS) provides insights into genome-wide mutations and ca...
High-throughput next-generation sequencing (NGS) provides insights into genome-wide mutations and ca...
High-throughput next-generation sequencing (NGS) provides insights into genome-wide mutations and ca...
High-throughput next-generation sequencing (NGS) provides insights into genome-wide mutations and ca...
High-throughput next-generation sequencing (NGS) provides insights into genome-wide mutations and ca...
BackgroundTumor mutation burden (TMB) has been recognized as a predictive biomarker for immunotherap...
Molecular profiling with next generation sequencing (NGS) delivers key information on mutant gene se...
Tumor mutational burden (TMB) is a promising predictive biomarker for cancer immunotherapy. Patients...
High-throughput next-generation sequencing (NGS) provides insights into genome-wide mutations and ca...
High-throughput next-generation sequencing (NGS) provides insights into genome-wide mutations and ca...
High-throughput next-generation sequencing (NGS) provides insights into genome-wide mutations and ca...
High-throughput next-generation sequencing (NGS) provides insights into genome-wide mutations and ca...
High-throughput next-generation sequencing (NGS) provides insights into genome-wide mutations and ca...
High-throughput next-generation sequencing (NGS) provides insights into genome-wide mutations and ca...
High-throughput next-generation sequencing (NGS) provides insights into genome-wide mutations and ca...
High-throughput next-generation sequencing (NGS) provides insights into genome-wide mutations and ca...
High-throughput next-generation sequencing (NGS) provides insights into genome-wide mutations and ca...
High-throughput next-generation sequencing (NGS) provides insights into genome-wide mutations and ca...
High-throughput next-generation sequencing (NGS) provides insights into genome-wide mutations and ca...
High-throughput next-generation sequencing (NGS) provides insights into genome-wide mutations and ca...
BackgroundTumor mutation burden (TMB) has been recognized as a predictive biomarker for immunotherap...
Molecular profiling with next generation sequencing (NGS) delivers key information on mutant gene se...
Tumor mutational burden (TMB) is a promising predictive biomarker for cancer immunotherapy. Patients...